Severe Hepatic Impairment Clinical Trial
Official title:
An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143 in Participants With Severe Hepatic Impairment and in Matched Healthy Adults
Participants aged 18 to 75 years with severe hepatic impairment (Child-Pugh class C) who meet the full study eligibility criteria will be enrolled into the study. For each participant with severe hepatic impairment, a corresponding healthy participant will be enrolled who matches with regard to age, sex, and BMI. A single dose of 55-mg EQ143 tablet will be administered in the morning on Day 1, and participants will remain for 5 days (4 nights) in the study center for collection of blood samples and safety monitoring. Participants will attend outpatient follow-up visits on Days 5, 6, 8, and 9 for additional blood sampling and safety assessments. The study will measure and describe the concentrations of EQ143 and its metabolite (HAS-719) in plasma over the course of 9 days (including calculation of PK parameters), the degree of EQ143 and metabolite HAS-719 (and other metabolites, if applicable) binding to proteins in plasma, and the safety of administering a single dose of EQ143 in severely hepatically impaired and matched healthy participants
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03664544 -
PK Study in Subjects With Severe Hepatic Impairment
|
Phase 1 | |
| Completed |
NCT05116826 -
Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients
|
Phase 1 | |
| Completed |
NCT02170220 -
Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment
|
Phase 1 | |
| Terminated |
NCT03818672 -
Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects
|
Phase 4 | |
| Completed |
NCT02138162 -
A Study to Investigate the Effect of Severely Diminished Liver Function on the Metabolism, Safety, and Tolerability of a Single Oral Dose of Enzalutamide in Men
|
Phase 1 | |
| Completed |
NCT03865446 -
Evaluate Severe Hepatic Impairment on Dacomitinib PK
|
Phase 1 | |
| Recruiting |
NCT05224609 -
A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction
|
Phase 1 |